These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27222018)

  • 1. A Review of Treatment Options for Progressive Supranuclear Palsy.
    Stamelou M; Höglinger G
    CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive supranuclear palsy.
    Giagkou N; Höglinger GU; Stamelou M
    Int Rev Neurobiol; 2019; 149():49-86. PubMed ID: 31779824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
    Williams DR; de Silva R; Paviour DC; Pittman A; Watt HC; Kilford L; Holton JL; Revesz T; Lees AJ
    Brain; 2005 Jun; 128(Pt 6):1247-58. PubMed ID: 15788542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions in progressive supranuclear palsy.
    Koros C; Stamelou M
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S93-5. PubMed ID: 26459661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.
    Stejskalova Z; Rohan Z; Rusina R; Tesar A; Kukal J; Kovacs GG; Bartos A; Matej R
    BMC Neurol; 2019 Mar; 19(1):42. PubMed ID: 30894142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy.
    Sakae N; Josephs KA; Litvan I; Murray ME; Duara R; Uitti RJ; Wszolek ZK; Graff-Radford NR; Dickson DW
    Mov Disord; 2019 Nov; 34(11):1655-1662. PubMed ID: 31433871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of progressive supranuclear palsy].
    Finali G; Piccinin GL; Piccirilli M; Stefano E
    Clin Ter; 1989 Jun; 129(5):339-51. PubMed ID: 2569956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.
    Liscic RM; Srulijes K; Gröger A; Maetzler W; Berg D
    Acta Neurol Scand; 2013 May; 127(5):362-70. PubMed ID: 23406296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational therapeutic approaches to progressive supranuclear palsy.
    Stamelou M; de Silva R; Arias-Carrión O; Boura E; Höllerhage M; Oertel WH; Müller U; Höglinger GU
    Brain; 2010 Jun; 133(Pt 6):1578-90. PubMed ID: 20472654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA
    Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnosis of progressive supranuclear palsy: current opinions and challenges.
    Ali F; Josephs K
    Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine-induced myoclonus in a patient with progressive supranuclear palsy.
    Yarnall AJ; Burn DJ
    Age Ageing; 2012 Sep; 41(5):695-6. PubMed ID: 22421702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalamic hypoperfusion in early stage of progressive supranuclear palsy (Richardson's syndrome): report of an autopsy-confirmed case.
    Kobayashi Z; Akaza M; Ishihara S; Tomimitsu H; Inadome Y; Arai T; Akiyama H; Shintani S
    J Neurol Sci; 2013 Dec; 335(1-2):224-7. PubMed ID: 24075472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive supranuclear palsy: clinical features, pathophysiology and management.
    Rajput A; Rajput AH
    Drugs Aging; 2001; 18(12):913-25. PubMed ID: 11888346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor, cognitive and behavioral differences in MDS PSP phenotypes.
    Picillo M; Cuoco S; Tepedino MF; Cappiello A; Volpe G; Erro R; Santangelo G; Pellecchia MT; Barone P;
    J Neurol; 2019 Jul; 266(7):1727-1735. PubMed ID: 30989369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive Supranuclear Palsy: an Update.
    Armstrong MJ
    Curr Neurol Neurosci Rep; 2018 Feb; 18(3):12. PubMed ID: 29455271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.
    Josephs KA; Boeve BF; Duffy JR; Smith GE; Knopman DS; Parisi JE; Petersen RC; Dickson DW
    Neurocase; 2005 Aug; 11(4):283-96. PubMed ID: 16093229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creutzfeldt-Jakob disease presenting as progressive supranuclear palsy.
    Josephs KA; Tsuboi Y; Dickson DW
    Eur J Neurol; 2004 May; 11(5):343-6. PubMed ID: 15142229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.
    Shoeibi A; Olfati N; Litvan I
    Expert Opin Investig Drugs; 2018 Apr; 27(4):349-361. PubMed ID: 29602288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive supranuclear palsy: a current review.
    Lubarsky M; Juncos JL
    Neurologist; 2008 Mar; 14(2):79-88. PubMed ID: 18332837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.